Clonal Hematopoiesis of Indeterminate Potential

Area of Science:

• Hematology
• Genetics
• Oncology

Background:

• Molecular genetic testing is increasingly used for cytopenia diagnosis.
• Detects mutations without morphological correlates, aiding in differentiating myelodysplastic syndrome (MDS).
• A new entity, CHIP, is recognized as a potential precursor to myeloid diseases.

Purpose of the Study:

• To define Clonal Hematopoiesis of Indeterminate Potential (CHIP).
• To understand its prevalence, associated mutations, and transformation risk.
• To guide diagnostic and monitoring strategies for CHIP.

Main Methods:

• Literature review using PubMed.
• Search terms included "clonal hematopoiesis," "acute myeloid leukemia," and "myelodysplastic syndrome."

Main Results:

• CHIP is characterized by somatic mutations in blood/bone marrow cells without other neoplasia criteria.
• Prevalence increases with age, affecting ~10% of those 70-80 years old.
• Common mutations include DNMT3A, TET2, ASXL1; transformation risk is 0.5-1% annually.

Conclusions:

• CHIP should be considered in the differential diagnosis of peripheral blood cytopenia.
• Understanding CHIP is crucial for interpreting the clinical significance of clonal hematopoiesis.
• Monitoring includes repeat CBCs at 3 months and annually for incidental CHIP findings.